Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Neuroendocrine Tumors 3Meningioma 3Prostatic Neoplasms 2Gastro-enteropancreatic neuroendocrine tumor 2Neuroblastoma 1Neoplasms 1Glioma 1Ganglioneuroma 1Ganglioneuroblastoma 1Disease 1Carcinoid Tumor 1Breast Neoplasms 1Breast Cancer Metastatic 1Advanced Gastroenteropancreatic Neuroendocrine Tumor 1

Interventions

Trastuzumab 594Paclitaxel 561Cyclophosphamide 545Docetaxel 478Capecitabine 387Letrozole 350Fulvestrant 310Doxorubicin 285Carboplatin 277Tamoxifen 257Anastrozole 219exemestane 211Epirubicin 210Radiotherapy 197Bevacizumab 189pertuzumab 175Gemcitabine 163Vinorelbine 162pembrolizumab 161Lapatinib 161palbociclib 152Exercise 132Fluorouracil 118Albumin-Bound Paclitaxel 116eribulin 108Magnetic Resonance Spectroscopy 108130-nm albumin-bound paclitaxel 107Everolimus 103Taxes 96Cisplatin 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Breast Neoplasms × Ga(III)-DOTATOC × Clear all
NCT04529044 2025-10-30

177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer

OHSU Knight Cancer Institute

Phase 2 Not yet recruiting
10 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡